ProKidney Corp

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

• ↑Complete enrollment of 320 patients in Phase 3 PROACT trial; topline data due Q2 2027
• ↑$181.6 million cash reserves fund operations through mid-2027, enabling pipeline advancement
• ↓Q2 2026 revenue $0.15 million, missing estimates by 31.8%, highlighting weak commercial dynamics